-
Mashup Score: 65Chemotherapy-free treatment targeting fusions and driver mutations in KRAS wild-type pancreatic ductal adenocarcinoma, a case series - 4 month(s) ago
KRAS wild-type (WT) pancreatic ductal adenocarcinoma (PDAC) represents a distinct entity with unique biology. The therapeutic impact of matched targeted therapy in these patients in a real-world setting, to date, is less established.The aim of our study …
Source: www.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 33Outpatient Administration of CAR T-cell Therapies Using a Strategy of No Remote Monitoring and Early CRS Intervention - PubMed - 4 month(s) ago
Recent studies demonstrating the feasibility of outpatient chimeric antigen receptor modified (CAR) T-cell therapy administration are either restricted to CARs with 41BB costimulatory domains or employ intensive at-home monitoring. We report outcomes of outpatient administration of all commercially …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet-
Outpatient Administration of CAR T-cell Therapies Using a Strategy of No Remote Monitoring and Early CRS Intervention - PubMed This is important https://t.co/TppwSUoZDk
-
-
Mashup Score: 14Survival Benefit Associated With Participation in Clinical Trials of Anticancer Drugs: A Systematic Review and Meta-analysis - PubMed - 6 month(s) ago
Many studies suggest a survival benefit for cancer trial participants. However, these benefits were not detected in studies using designs addressing important sources of bias and confounding. Pooled results of high-quality studies are not consistent with a beneficial effect of trial participation on …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet-
This “study” “showed” that cancer pts don’t live longer on clinical trials. They selected 39 trials (years 2000 -2022) (of >20,000 trials done) & found longer OS. Then they analysed subset of those 39 trials & found no OS benefit. Seriously? https://t.co/j4QpY9S4ea
-
-
Mashup Score: 2
Many diseases can have similar genetic changes to those seen in cancer. This review summarizes these genetic changes along with cancer drugs that have benefit or potential benefit in non-cancer conditions.
Source: www.cell.comCategories: General Medicine News, Hem/OncsTweet-
RT @agingdoc1: Reverse repurposing: Potential utility of cancer drugs in nonmalignant illnesses @Dr_R_Kurzrock https://t.co/iFWMVNfFrG
-
-
Mashup Score: 7Former UCLA oncologist awarded $14 million in retried gender discrimination case - Daily Bruin - 6 month(s) ago
The Los Angeles Superior Court awarded $14 million to a former UCLA oncologist Thursday following an eight-year battle over her gender discrimination lawsuit. Dr. Lauren Pinter-Brown, a former hematologic oncologist at Ronald Reagan UCLA Medical Center, sued the UC Board of Regents in 2016, alleging that she was discriminated against by her male colleagues and that she was receiving, on average, $200,000 less than them annually.
Source: dailybruin.comCategories: General Medicine News, Hem/OncsTweet-
Former UCLA oncologist awarded $14 million in retried gender discrimination case - Daily Bruin Pinter-Brown case. https://t.co/HCQwLAqe2S
-
-
Mashup Score: 7Former UCLA oncologist awarded $14 million in retried gender discrimination case - Daily Bruin - 6 month(s) ago
The Los Angeles Superior Court awarded $14 million to a former UCLA oncologist Thursday following an eight-year battle over her gender discrimination lawsuit. Dr. Lauren Pinter-Brown, a former hematologic oncologist at Ronald Reagan UCLA Medical Center, sued the UC Board of Regents in 2016, alleging that she was discriminated against by her male colleagues and that she was receiving, on average, $200,000 less than them annually.
Source: dailybruin.comCategories: General Medicine News, Hem/OncsTweet-
Former UCLA oncologist awarded $14 million in retried gender discrimination case - Daily Bruin Pinter-Brown case. https://t.co/HCQwLAqe2S
-
-
Mashup Score: 2High indoleamine 2,3-dioxygenase transcript levels predict better outcome after front-line cancer immunotherapy - 8 month(s) ago
Immunology; Molecular biology; Cancer
Source: www.cell.comCategories: General Medicine News, Hem/OncsTweet-
RT @waraonc23: https://t.co/sd8D8PTsBC Let me re-post! Our work dissecting mRNA expression of immune markers is now available! @iScience_C…
-
-
Mashup Score: 37What it feels like: Taking a colorectal cancer diagnosis and turning it into hope for others - 8 month(s) ago
Barry Stein first noticed blood in his stool when he was in his 30s and didn’ t think much of it. After further reflection, Stein thought that checking things out may not be such a bad idea. That inkling to seek out medical testing could be what saved Barry Stein’s life: shortly after that, he was diagnosed with early-onset colorectal cancer. Unfortunately, the cancer was no longer confined to his colon, as it had begun spreading to other areas of the body. Because of that, and the lack of viable treatment
Source: www.healthing.caCategories: General Medicine News, Hem/OncsTweet-
FT3 Board meeting. Just met him. Barry Stein! Metastatic CRC (liver/ lungs) in 1995. Surgery & hepatic arterial infusion. Amazing; it’s 2024 and he is here looking great & making a difference for others 👉Turning a diagnosis into hope for others. https://t.co/PLcIxPp2Qf
-
-
Mashup Score: 47Outcome differences by sex in oncology clinical trials - 8 month(s) ago
Nature Communications – The role of sex differences in response to cancer therapy remains unclear but this could be improved by reporting sex comparisons of outcomes in clinical trials. Here, the…
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet-
Only 472 of 89,221 (0.5%) trials looked at gender differences. Even so, there were differences Nature Communications https://t.co/EDmKLLpvCr https://t.co/ygnPpAmVaA
-
-
Mashup Score: 20OX40/OX40 ligand and its role in precision immune oncology - PubMed - 8 month(s) ago
Immune checkpoint inhibitors have changed the treatment landscape for various malignancies; however, their benefit is limited to a subset of patients. The immune machinery includes both mediators of suppression/immune evasion, such as PD-1, PD-L1, CTLA-4, and LAG-3, all of which can be inhibited by …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet-
Hot off the press. More precision immunotherapy. https://t.co/Y5S6qf7pdl 🔥🔥🔥🎯🎯👉 https://t.co/To0hM10rPy
-
Chemotherapy-free matched targeted therapy in pancreatic cancer! https://t.co/XyHXRCEh0J https://t.co/455lfCkgJB